Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090725 | 1.00 | TDP1 (0.33) | TDP1KDM4EPOLBMAPTSMN1; SMN2 | |
| SCHEMBL18544003 | 0.79 | RAPGEF4 (0.37) | KDM4EMAPT | |
| SCHEMBL18544005 | 0.79 | RAPGEF4 (0.37) | KDM4EMAPT | |
| SCHEMBL14670497 | 0.79 | RAPGEF4 (0.37) | KDM4EMAPT | |
| SCHEMBL18631853 | 0.75 | KDM4E (0.32) | TDP1KDM4EPOLB | |
| SCHEMBL18631852 | 0.75 | KDM4E (0.32) | TDP1KDM4EPOLB | |
| SCHEMBL5799242 | 0.74 | POLB (0.32) | POLB | |
| SCHEMBL18631841 | 0.74 | RAB9A (0.33) | TDP1KDM4EPOLBMAPTRAB9A | |
| SCHEMBL18631842 | 0.74 | RAB9A (0.33) | TDP1KDM4EPOLBMAPTRAB9A | |
| SCHEMBL21192650 | 0.73 | LMNA (0.41) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036713-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | EVONIK DEGUSSA GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1991520-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | Evonik Degussa GmbH (DE) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007101769-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | EVONIK DEGUSSA GMBH (DE) | 2007-09-13 | — | — | WO | disclosed |
| US-20070213540-A1 | Process for the hydrogenation of imines | DEGUSSA AG (DE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036713-A1 | PROCESS FOR THE HYDROGENATION OF IMINES | IPO5, IPO4, HRH3 | TDP1 3165/4885KDM4E 2212/4885POLB 649/4885 |
| US-20070213540-A1 | Process for the hydrogenation of imines | KCNH3, KCNH2, KMO | TDP1 4093/4885KDM4E 1507/4885POLB 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.